astrazeneca oral glp 1 AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. Results from the VISTA and SOLSTICE trials, published simultaneously AstraZeneca's ECC5004: Pioneering oral GLP-1RA

We're focused on the right number

Weight regain after discontinuation follows a predictable pattern

However, studies using beta-3-adrenergic receptor knockout mice revealed a more complex picture: Long-term AOD-9604 treatment failed to produce weight loss in beta-3-AR knockout mice Acute administration still increased energy expenditure and fat oxidation in knockout mice This suggests beta-3-AR expression enhancement contributes to, but does not directly mediate, lipolytic effects The peptide appears to work through an unidentified receptor mechanism that subsequently influences beta-3-adrenergic signaling pathways

One oral formulation (semaglutide tablets, Rybelsus) is also available

Digestion Changes: By slowing down digestion, GLP-1 RAs may affect how well your body absorbs some vitamins and minerals

On November 8, 2023, the FDA approved Zepbound for use in adults with obesity or those who are overweight with at least one weight-related condition